Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
Stopped early · Phase 2
Conditions studied: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
In brief
The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin SB0/+), or homozygous b0/+ thalassemia or severe B0/+ thalassemia variants. Participation in this project will be for one year, with follow up evaluations done every 6 months thereafter for 10 years or until participants are 18 years old.
Key facts
- Study ID
- NCT00040417
- Run by
- Baylor College of Medicine
- People needed
- 15
- Starts
- 2000-08-01
- Expected to finish
- 2003-11-21
- Last updated by the study team
- 2020-01-18
Who can join
Age: 0 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Texas Children's Hospital — Houston, Texas, United States
- The Methodist Hospital — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.